New hope for behçet patients: drug targets painful ulcers and eye inflammation
NCT ID NCT02648581
First seen Nov 01, 2025 · Last updated Jun 13, 2026 · Updated 29 times
Summary
This study tested a drug called ustekinumab in 16 adults with Behçet disease, a condition that causes painful mouth sores and eye swelling. The goal was to see if the drug could reduce the number of mouth ulcers and calm eye inflammation over 24 weeks. While not a cure, the treatment aims to control symptoms and improve quality of life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BEHÇET DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hôpital Cochin, Department of Internal Medicine, National Reference Center for Autoimmune and Systemic Diseases
Paris, Paris, 75014, France
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.